We anticipate that our present work showing bortezomib mediated downregulation of SKP2 as a result of its correlation with p27Kip1 stabilization and inhibition of CML cell proliferation is a novel finding that can have potential implications for future pre-clinical and clinical studies in CML. This evidence concerns the gene CDKN1B and chronic myelogenous leukemia, BCR-ABL1 positive.